Activated AKT, which is observed in ~ 70% of GBM patients, particularly in GBM with PTEN loss, and the disruption of RTK/PI3K signaling, are considered to be some of the major mechanisms driving GBM tumorigenesis and progression [36, 37]. The gene discussed is AKT1; the disease is glioblastoma.